ForPatients
*by Roche*

Hemophilia A

# A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN2)

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

| Trial Status | Trial Runs In | Trial Identifier |
|---|---|---|
| Completed | 10 Countries | NCT02795767 2016-000073-21, HAVEN2 BH29992 |

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

## *Trial Summary:*

This non-randomized, multicenter, open-label, Phase III clinical study will evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric participants with hemophilia A with FVIII inhibitors. This study will open two additional non-randomized cohorts to investigate once every 2 weeks (Q2W) and once every 4 weeks (Q4W) regimens in pediatric participants.

**Hoffmann-La Roche**
Sponsor

**Phase 3**
Phase

**NCT02795767 2016-000073-21, HAVEN2 BH29992**
Trial Identifiers

## *Eligibility Criteria:*

| Gender | Age | Healthy Volunteers |
|---|---|---|
| All | <= 17 Years | No |

© 2022 F. Hoffmann-La Roche Ltd